Astaxanthin is a xanthophyll carotenoid produced by the microalgae Haematococcus pluvialis under conditions of nutrient stress or high UV exposure. It is the pigment responsible for the characteristic red-pink colour of salmon, shrimp, and flamingos — animals that accumulate it through their diet rather than producing it themselves.
From a chemistry standpoint, astaxanthin is structurally similar to beta-carotene but with polar end-groups (keto and hydroxyl groups) on both ends of the molecule. This gives it a unique positioning in cell membranes — spanning the full lipid bilayer rather than sitting within it — which is relevant to understanding why delivery format affects how much of the supplemental dose reaches systemic circulation.
The Absorption Problem: Why Astaxanthin Is Format-Sensitive
Astaxanthin is fat-soluble. This single chemical property creates the core bioavailability challenge: fat-soluble compounds require a lipid carrier for absorption through the intestinal epithelium. Without adequate lipid in the gastrointestinal environment — either from co-ingested food or from the supplement formulation itself — astaxanthin passes through the gut largely unabsorbed.
The absorption pathway follows that of dietary lipids. After oral ingestion, astaxanthin must:
- Be released from the supplement matrix into the GI lumen
- Incorporate into mixed micelles with bile salts and dietary lipids
- Be taken up by enterocytes (intestinal epithelial cells)
- Be packaged into chylomicrons and transported via lymph to systemic circulation
Each step is dependent on the lipid environment. A supplement taken in a fasted state — or in a format that does not provide its own lipid carrier — will have substantially lower bioavailability than the same dose taken with a fat-containing meal or in an oil-based format.
Natural vs. Synthetic Astaxanthin
Most commercially sold astaxanthin falls into one of two categories:
Natural astaxanthin (from H. pluvialisor other marine sources) is a mixture of free astaxanthin, mono-esters, and di-esters — where “ester” means the hydroxyl groups on the astaxanthin molecule are bound to fatty acids. The esterified forms are the predominant form in nature and in commercially produced algal astaxanthin. Esterification increases the molecule’s lipophilicity, making it more stable but requiring enzymatic hydrolysis in the gut before absorption.
Synthetic astaxanthin is produced via chemical synthesis and is predominantly free (non-esterified). It is less expensive to produce and is widely used in aquaculture (salmon farming). It is generally not used in human supplements marketed as natural.
AstaReal® — the form used in Moana Natura’s Marine Glow — is natural astaxanthin from H. pluvialis, produced in a controlled indoor facility in Sweden. This standardized cultivation eliminates the contamination variability associated with outdoor pond cultivation.
Format Comparison: Bioavailability by Delivery Vehicle
Bioavailability studies comparing astaxanthin formats have consistently shown that delivery vehicle is the primary determinant of plasma astaxanthin concentration — more significant than dose within a given format range.
| Format | Mechanism | Relative bioavailability | Notes |
|---|---|---|---|
| Dry powder / capsule | Depends on dietary fat for micelle formation | Low (reference) | Absorption highly variable; dramatically food-dependent |
| Oil suspension (softgel) | Lipid carrier pre-incorporated; self-emulsifying | Moderate (3–4×) | Standard commercial form; better than dry but still food-dependent |
| Esterified in oil (AstaReal®) | Ester hydrolysis + lipid emulsification | Moderate–high | Industry standard; esterification improves stability, minor absorption difference |
| Nanoparticle emulsion | Reduced particle size improves dispersion | High | Studied in food science context; not widely commercialized for supplements |
| Liposomal / phospholipid-complex | Phospholipid bilayer provides direct membrane fusion pathway | Highest | Bypasses standard lipid digestion pathway; highest plasma AUC in comparative studies |
A 2011 study by Coral-Hinostroza et al. comparing free astaxanthin and astaxanthin mono- and di-esters found that the esterified forms showed marginally higher plasma concentrations in humans — consistent with the stability advantage of esterification protecting the molecule during digestion. However, the magnitude of difference between ester forms is small compared to the difference between any oil-based form and a dry powder taken without fat.
The practical implication: if you take a dry astaxanthin capsule on an empty stomach, a significant fraction of the dose will not be absorbed regardless of stated potency. The format is not optional — it is the primary absorption variable.
AstaReal® at 6 mg: Why This Dose and This Form
The human absorption literature on astaxanthin has examined doses from 0.5 mg to 40 mg. The dose-response curve for plasma concentration is non-linear — the relationship between dose and plasma area under the curve (AUC) flattens above approximately 8–12 mg in most studies, suggesting diminishing returns at high doses.
The 6 mg dose in AstaReal® formulations represents the range at which the dose-response curve is still on its ascending portion, where incremental increases in dose produce proportional increases in plasma concentration. Above this range, additional dose does not produce proportional plasma concentration increases — the absorption mechanism is approaching saturation.
At 6 mg in an oil-based format, AstaReal® delivers astaxanthin within the dose range supported by the human bioavailability literature for achieving measurable plasma concentrations. Whether higher or lower doses are appropriate depends on individual baseline status and application context — 6 mg is not a universal answer, but it is a defensible starting point based on the absorption data.
EFSA Status for Astaxanthin
As of 2026, astaxanthin has no authorized health claims under EU Regulation 432/2012. EFSA has evaluated astaxanthin-related claims and found insufficient evidence to authorize claims related to antioxidant protection, skin health, cardiovascular function, or other endpoints. This means supplement copy that attributes any health outcome to astaxanthin specifically is making an unauthorized claim under EU law.
The claims that are authorized in skin-focused formulas containing astaxanthin come from the co-ingredients, not the astaxanthin itself:
- Vitamin C contributes to normal collagen formation for the normal function of skin (EU Regulation 432/2012, IDs 130–134, 147)
- Zinc contributes to the maintenance of normal skin (EU Regulation 432/2012, ID 11)
- Biotin contributes to the maintenance of normal skin (EU Regulation 432/2012, ID 20)
In Marine Glow, the Vitamin C (80 mg, 100% NRV) and Zinc components carry the authorized skin claims. The AstaReal® astaxanthin (6 mg) is a characterized compositional ingredient — its role is described in terms of its biological source and format properties, not as an outcome claim.
Practical Considerations for Astaxanthin Supplementation
Take with fat: Even with an oil-based formula, co-ingestion with a fat-containing meal improves absorption. The bile salt secretion stimulated by dietary fat enhances micelle formation and enterocyte uptake.
Consistency matters more than timing: Astaxanthin accumulates in tissues over time. Studies that measured outcomes beyond plasma concentrations — such as skin or cellular accumulation — used supplementation periods of 4–12 weeks. A single dose is not a useful metric of benefit; consistent daily intake over weeks to months is the relevant protocol.
Stability: Astaxanthin degrades under oxidative conditions. Esterified forms (like AstaReal®) are more stable than free astaxanthin under light and heat exposure. Encapsulation in an oil-based softgel or liposomal format protects the molecule from oxidation during storage.